Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 15 OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3210 Carcinoma, Non-Small-Cell Lung 2721 Breast Neoplasms 2547 Colorectal Neoplasms 1454 Prostatic Neoplasms 1303 Neoplasm Metastasis 1292 Multiple Myeloma 1109 Melanoma 1101 Ovarian Neoplasms 1001 Lung Neoplasms 941 Recurrence 921 Leukemia, Myeloid, Acute 876 Pancreatic Neoplasms 830 Lymphoma, Non-Hodgkin 766 Lymphoma 713 Stomach Neoplasms 691 Carcinoma, Renal Cell 658 Carcinoma, Hepatocellular 645 Leukemia, Lymphocytic, Chronic, B-Cell 560 Squamous Cell Carcinoma of Head and Neck 546 Lymphoma, Follicular 515 Head and Neck Neoplasms 488 Glioblastoma 472 Small Cell Lung Carcinoma 444 Lymphoma, Large B-Cell, Diffuse 440 Triple Negative Breast Neoplasms 433 Advanced Solid Tumors 430 Leukemia 426 Uterine Cervical Neoplasms 418 Urinary Bladder Neoplasms 405

Interventions

Certolizumab Pegol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Fistula × Clear all

NCT00354367 2012-05-28

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

UCB Pharma

Phase 3 Withdrawn

Crohn Disease, Fistula

Data powered by HemOnc (CC BY 4.0) Colophon ⚡